These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1520 related articles for article (PubMed ID: 19651174)

  • 1. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies.
    Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC
    J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine.
    Lin CT; Yen CF; Shaw SW; Yen TC; Chen YJ; Soong YK; Lai CH
    Vaccine; 2009 Dec; 27(52):7352-8. PubMed ID: 19781679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
    Di Bonito P; Grasso F; Mochi S; Petrone L; Fanales-Belasio E; Mei A; Cesolini A; Laconi G; Conrad H; Bernhard H; Dembek CJ; Cosma A; Santini SM; Lapenta C; Donati S; Muratori C; Giorgi C; Federico M
    Virology; 2009 Dec; 395(1):45-55. PubMed ID: 19800648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MyD88 signal is required for more efficient induction of Ag-specific adaptive immune responses and antitumor resistance in a human papillomavirus E7 DNA vaccine model.
    Sin JI
    Vaccine; 2011 May; 29(24):4125-31. PubMed ID: 21496466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.
    Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S
    Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene.
    Poláková I; Pokorná D; Dusková M; Smahel M
    Vaccine; 2010 Feb; 28(6):1506-13. PubMed ID: 20003917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection.
    Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R
    Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
    Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
    Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.